Skip to main content
Top
Published in: American Journal of Clinical Dermatology 2/2021

01-03-2021 | Anaphylaxis | Review Article

Pediatric Mastocytosis: Recognition and Management

Author: Julie V. Schaffer

Published in: American Journal of Clinical Dermatology | Issue 2/2021

Login to get access

Abstract

Mastocytosis is a heterogeneous group of disorders characterized by the accumulation of clonal mast cells in organs such as the skin and bone marrow. In contrast to adults, most affected children have only cutaneous involvement. This article reviews the molecular pathogenesis, skin findings, mast cell mediator-related symptoms, evaluation, and management of childhood-onset mastocytosis, noting differences from adult-onset disease. Current classification of cutaneous mastocytosis and the natural histories of different variants in pediatric patients are highlighted, with a focus on clinical manifestations with prognostic implications. A practical algorithm is provided to guide clinical assessment, laboratory and other investigations, and longitudinal monitoring, including recognition of hepatosplenomegaly as a marker of systemic disease and utilization of allele-specific quantitative PCR (ASqPCR) to detect KIT mutations in the peripheral blood. Updated information and consensus-based recommendations regarding possible triggers of mast-cell degranulation (e.g., physical, medications) are discussed, with an emphasis on patient-specific factors and avoiding excessive parental concern. Lastly, an individualized, stepwise approach to treatment of symptoms, skin-directed therapy, and potential use of kinase inhibitors for severe systemic disease is outlined.
Literature
1.
go back to reference Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis (mast cell disease). In: Swerdlow SH, Campo PE, Harris NL, et al., editors. World Health Organization (WHO) classification of tumours: pathology and genetics of tumours of the haematopoietic and lymphoid tissues, vol. 2. Lyon (France): IARC Press; 2008. p. 54–63. Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis (mast cell disease). In: Swerdlow SH, Campo PE, Harris NL, et al., editors. World Health Organization (WHO) classification of tumours: pathology and genetics of tumours of the haematopoietic and lymphoid tissues, vol. 2. Lyon (France): IARC Press; 2008. p. 54–63.
2.
go back to reference Valent P, Akin C, Dean D. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420–7.PubMedPubMedCentral Valent P, Akin C, Dean D. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420–7.PubMedPubMedCentral
3.
go back to reference Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin N Am. 2014;34:207–18. Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin N Am. 2014;34:207–18.
4.
go back to reference Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35–45.PubMed Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35–45.PubMed
5.
go back to reference Heide R, Tank B, Oranje AP. Mastocytosis in childhood. Pediatr Dermatol. 2002;19:375–81.PubMed Heide R, Tank B, Oranje AP. Mastocytosis in childhood. Pediatr Dermatol. 2002;19:375–81.PubMed
6.
go back to reference Wiechers T, Rabenhorst A, Schick T, et al. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J Allergy Clin Immunol. 2015;136:1581–90.PubMed Wiechers T, Rabenhorst A, Schick T, et al. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J Allergy Clin Immunol. 2015;136:1581–90.PubMed
7.
go back to reference Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.PubMed Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.PubMed
8.
go back to reference Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519–28.PubMed Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519–28.PubMed
9.
go back to reference Hannaford R, Rogers M. Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol. 2001;42:15–21.PubMed Hannaford R, Rogers M. Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol. 2001;42:15–21.PubMed
10.
go back to reference Middelkamp Hup MA, Heide R, Tank B, et al. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol. 2002;16:115–20.PubMed Middelkamp Hup MA, Heide R, Tank B, et al. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol. 2002;16:115–20.PubMed
11.
go back to reference Kiszewski AE, Duran-Mckinster C, Orozco-Covarrubias L, et al. Cutaneous mastocytosis in children: a clinical analysis of 71 cases. J Eur Acad Dermatol Venereol. 2004;18:285–90.PubMed Kiszewski AE, Duran-Mckinster C, Orozco-Covarrubias L, et al. Cutaneous mastocytosis in children: a clinical analysis of 71 cases. J Eur Acad Dermatol Venereol. 2004;18:285–90.PubMed
12.
go back to reference Ben-Amitai D, Metzker A, Cohen HA. Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J. 2005;7:320–2.PubMed Ben-Amitai D, Metzker A, Cohen HA. Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J. 2005;7:320–2.PubMed
13.
go back to reference Alvarez-Twose I, Vañó-Galván S, Sánchez-Muñoz L, et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy. 2012;67:813–21.PubMed Alvarez-Twose I, Vañó-Galván S, Sánchez-Muñoz L, et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy. 2012;67:813–21.PubMed
14.
go back to reference Lange M, Niedoszytko M, Renke J, et al. Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol. 2013;27:97–102.PubMed Lange M, Niedoszytko M, Renke J, et al. Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol. 2013;27:97–102.PubMed
15.
go back to reference Méni C, Georgia-Lavialle S, de Peufeilhoux LLS, et al. Pediatric mastocytosis: long-term follow up of 53 patients with whole sequencing of KIT. A prospective study. Br J Dermatol. 2018;179:925–32.PubMed Méni C, Georgia-Lavialle S, de Peufeilhoux LLS, et al. Pediatric mastocytosis: long-term follow up of 53 patients with whole sequencing of KIT. A prospective study. Br J Dermatol. 2018;179:925–32.PubMed
16.
go back to reference Leszczynska M, Kwon C, Juarez M, et al. Cutaneous mastocytosis in a pediatric population: clinical features and long-term follow-up. In: Poster, Society of Pediatric Dermatology Annual Meeting, July 2019 Leszczynska M, Kwon C, Juarez M, et al. Cutaneous mastocytosis in a pediatric population: clinical features and long-term follow-up. In: Poster, Society of Pediatric Dermatology Annual Meeting, July 2019
17.
go back to reference Bodemer C, Hermine O, Palmérini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130:804–15.PubMed Bodemer C, Hermine O, Palmérini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130:804–15.PubMed
18.
go back to reference Méni C, Bruneau J, Georgin-Lavialle S, et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015;172:642–51.PubMed Méni C, Bruneau J, Georgin-Lavialle S, et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015;172:642–51.PubMed
19.
go back to reference Arase N, Wataya-Kaneda M, Murota H, et al. Genotype and phenotype analysis of patients with pediatric cutaneous mastocytosis, especially wild-type KIT patients. J Dermatol. 2020;47:426–9.PubMed Arase N, Wataya-Kaneda M, Murota H, et al. Genotype and phenotype analysis of patients with pediatric cutaneous mastocytosis, especially wild-type KIT patients. J Dermatol. 2020;47:426–9.PubMed
20.
go back to reference Ma D, Stence AA, Bossler AB, et al. Identification of KIT activating mutations in paediatric solitary mastocytoma. Histopathology. 2014;64:218–25.PubMed Ma D, Stence AA, Bossler AB, et al. Identification of KIT activating mutations in paediatric solitary mastocytoma. Histopathology. 2014;64:218–25.PubMed
22.
go back to reference Tang X, Boxer M, Drummond A, et al. A germline mutation in KIT In familial diffuse cutaneous mastocytosis. J Med Genet. 2004;41:e88.PubMedPubMedCentral Tang X, Boxer M, Drummond A, et al. A germline mutation in KIT In familial diffuse cutaneous mastocytosis. J Med Genet. 2004;41:e88.PubMedPubMedCentral
23.
go back to reference Wang HJ, Lin ZM, Zhang J, et al. A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a Chinese family. Clin Exp Dermatol. 2014;39:146–9.PubMed Wang HJ, Lin ZM, Zhang J, et al. A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a Chinese family. Clin Exp Dermatol. 2014;39:146–9.PubMed
24.
go back to reference Caplan RM. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol. 1963;87:146–57.PubMed Caplan RM. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol. 1963;87:146–57.PubMed
25.
go back to reference Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol. 2003;48:508–16.PubMed Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol. 2003;48:508–16.PubMed
26.
go back to reference Hartmann K, Henz BM. Classification of cutaneous mastocytosis: a modified consensus proposal. Leuk Res. 2002;26:483–4.PubMed Hartmann K, Henz BM. Classification of cutaneous mastocytosis: a modified consensus proposal. Leuk Res. 2002;26:483–4.PubMed
28.
go back to reference Heinze A, Kuemmet TJ, Chiu YE, Galbraith SS. Longitudinal study of pediatric urticaria pigmentosa. Pediatr Dermatol. 2017;34:144–9.PubMed Heinze A, Kuemmet TJ, Chiu YE, Galbraith SS. Longitudinal study of pediatric urticaria pigmentosa. Pediatr Dermatol. 2017;34:144–9.PubMed
29.
go back to reference Uzzaman A, Maric I, Noel P, et al. Pediatric-onset mastocytosis: a long-term follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer. 2009;53:629–34.PubMedPubMedCentral Uzzaman A, Maric I, Noel P, et al. Pediatric-onset mastocytosis: a long-term follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer. 2009;53:629–34.PubMedPubMedCentral
30.
go back to reference Broesby-Olsen S, Dybedal I, Gulen T, et al. Multidisciplinary management of mastocytosis: Nordic Expert Group Consensus. Acta Derm Venereol. 2016;96:602–12.PubMed Broesby-Olsen S, Dybedal I, Gulen T, et al. Multidisciplinary management of mastocytosis: Nordic Expert Group Consensus. Acta Derm Venereol. 2016;96:602–12.PubMed
31.
go back to reference Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE. 2008;3:e1906.PubMedPubMedCentral Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE. 2008;3:e1906.PubMedPubMedCentral
32.
go back to reference Matito A, Azaña J, Torrelo A, Alvarez-Twose I. Cutaneous mastocytosis in adults and children: new classification and prognostic factors. Immunol Allergy Clin N Am. 2018;38:351–63. Matito A, Azaña J, Torrelo A, Alvarez-Twose I. Cutaneous mastocytosis in adults and children: new classification and prognostic factors. Immunol Allergy Clin N Am. 2018;38:351–63.
33.
go back to reference Kleewein K, Lang R, Diem A, et al. Diffuse cutaneous mastocytosis masquerading as epidermolysis bullosa. Pediatr Dermatol. 2011;28:720–5.PubMed Kleewein K, Lang R, Diem A, et al. Diffuse cutaneous mastocytosis masquerading as epidermolysis bullosa. Pediatr Dermatol. 2011;28:720–5.PubMed
34.
go back to reference Lange M, Niedoszytko M, Nedoszytko B, et al. Diffuse cutaneous mastocytosis: analysis of 10 cases and a brief review of the literature. J Eur Acad Dermatol Venereol. 2012;26:1565–71.PubMed Lange M, Niedoszytko M, Nedoszytko B, et al. Diffuse cutaneous mastocytosis: analysis of 10 cases and a brief review of the literature. J Eur Acad Dermatol Venereol. 2012;26:1565–71.PubMed
35.
go back to reference Hosking AM, Makdisi J, Ortenzio F, et al. Diffuse cutaneous mastocytosis: case report and literature review. Pediatr Dermatol. 2018;35:e348–52.PubMed Hosking AM, Makdisi J, Ortenzio F, et al. Diffuse cutaneous mastocytosis: case report and literature review. Pediatr Dermatol. 2018;35:e348–52.PubMed
36.
go back to reference Jenkinson H, Lundgren A, Carter M, et al. Management of a neonate with diffuse cutaneous mastocytosis: case report and literature review. Pediatr Dermatol. 2019;36:486–9.PubMed Jenkinson H, Lundgren A, Carter M, et al. Management of a neonate with diffuse cutaneous mastocytosis: case report and literature review. Pediatr Dermatol. 2019;36:486–9.PubMed
37.
go back to reference Chaudhary N, Shapiro N, Bhutada A, Rastogi S, et al. c-KIT-Positive fatal diffuse cutaneous mastocytosis with systemic manifestations in a neonate. J Pediatr Hematol Oncol. 2019;41:e338–40.PubMed Chaudhary N, Shapiro N, Bhutada A, Rastogi S, et al. c-KIT-Positive fatal diffuse cutaneous mastocytosis with systemic manifestations in a neonate. J Pediatr Hematol Oncol. 2019;41:e338–40.PubMed
38.
go back to reference Hudson A, Finlayson L. Diffuse cutaneous bullous mastocytosis and disseminated intravascular coagulation postvaccination: a case report. J Cutan Med Surg. 2016;20:596–9.PubMed Hudson A, Finlayson L. Diffuse cutaneous bullous mastocytosis and disseminated intravascular coagulation postvaccination: a case report. J Cutan Med Surg. 2016;20:596–9.PubMed
39.
go back to reference Leung A, Lam J, Leong K. Childhood solitary cutaneous mastocytoma: clinical manifestations, diagnosis, evaluation and management. Curr Pediatr Rev. 2019;15:42–6.PubMedPubMedCentral Leung A, Lam J, Leong K. Childhood solitary cutaneous mastocytoma: clinical manifestations, diagnosis, evaluation and management. Curr Pediatr Rev. 2019;15:42–6.PubMedPubMedCentral
40.
go back to reference Azaña JM, Velasco E, Torrelo A, et al. Mastocitomas: revision de 33 casos infantiles. Actas Dermosifiliogr. 1993;84:559–62. Azaña JM, Velasco E, Torrelo A, et al. Mastocitomas: revision de 33 casos infantiles. Actas Dermosifiliogr. 1993;84:559–62.
41.
go back to reference Requena López S, Matito A, Alvarez-Twose I, Torrelo A. Perioperative anaphylaxis in a patient with a solitary mastocytoma. Pediatr Dermatol. 2019;36:352–4.PubMed Requena López S, Matito A, Alvarez-Twose I, Torrelo A. Perioperative anaphylaxis in a patient with a solitary mastocytoma. Pediatr Dermatol. 2019;36:352–4.PubMed
42.
go back to reference Cheng YP, Hsiao CH, Dai YS. Nevoid urticaria pigmentosa along Blaschko’s lines. J Dermatol. 2012;39:665–6.PubMed Cheng YP, Hsiao CH, Dai YS. Nevoid urticaria pigmentosa along Blaschko’s lines. J Dermatol. 2012;39:665–6.PubMed
43.
go back to reference Merika EE, Bunker CB, Francis N, et al. A segmental rash in a young male: a quiz. Naevoid urticaria pigmentosa. Acta Derm Venereol. 2014;94:253–4.PubMed Merika EE, Bunker CB, Francis N, et al. A segmental rash in a young male: a quiz. Naevoid urticaria pigmentosa. Acta Derm Venereol. 2014;94:253–4.PubMed
44.
go back to reference Ahn H, Park H, Jeong K, et al. Atypical maculopapular cutaneous mastocytosis showing a nevus spilus-like lesion. Pediatr Dermatol. 2018;35:E306–7.PubMed Ahn H, Park H, Jeong K, et al. Atypical maculopapular cutaneous mastocytosis showing a nevus spilus-like lesion. Pediatr Dermatol. 2018;35:E306–7.PubMed
45.
go back to reference Tsutsui Y, Koga M, Koga K, Imafuku S. Child case of linear variant of telangiectasia macularis eruptive perstans. J Dermatol. 2019;46:e469–70.PubMed Tsutsui Y, Koga M, Koga K, Imafuku S. Child case of linear variant of telangiectasia macularis eruptive perstans. J Dermatol. 2019;46:e469–70.PubMed
46.
go back to reference Vano-Galvan S, Alvarez-Twose I, De las Heras E, et al. Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol. 2011;147:932–40.PubMed Vano-Galvan S, Alvarez-Twose I, De las Heras E, et al. Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol. 2011;147:932–40.PubMed
47.
go back to reference Azaña JM, Torrelo A, Mediero IG, Zambrano A, et al. Urticaria pigmentosa: a review of 67 pediatric cases. Pediatr Dermatol. 1994;11:102–6.PubMed Azaña JM, Torrelo A, Mediero IG, Zambrano A, et al. Urticaria pigmentosa: a review of 67 pediatric cases. Pediatr Dermatol. 1994;11:102–6.PubMed
48.
go back to reference Barnes M, Van L, DeLong L, et al. Severity of cutaneous findings predict the presence of systemic symptoms in pediatric maculopapular cutaneous mastocytosis. Pediatr Dermatol. 2014;31:271–5.PubMed Barnes M, Van L, DeLong L, et al. Severity of cutaneous findings predict the presence of systemic symptoms in pediatric maculopapular cutaneous mastocytosis. Pediatr Dermatol. 2014;31:271–5.PubMed
49.
go back to reference Gurnee E, Phung T, Guo E, et al. Neurocognitive dysfunction and anaphylaxis in pediatric maculopapular cutaneous mastocytosis. J Allergy Clin Immunol. 2020;8:409–10. Gurnee E, Phung T, Guo E, et al. Neurocognitive dysfunction and anaphylaxis in pediatric maculopapular cutaneous mastocytosis. J Allergy Clin Immunol. 2020;8:409–10.
50.
go back to reference Czarny J, Lange M, Lugowska-Umer H, Nowicki RJ. Cutaneous mastocytosis treatment: strategies, limitations, and perspectives. Postepy Dermatol Alergol. 2018;6:541–5. Czarny J, Lange M, Lugowska-Umer H, Nowicki RJ. Cutaneous mastocytosis treatment: strategies, limitations, and perspectives. Postepy Dermatol Alergol. 2018;6:541–5.
51.
go back to reference de Olano GD, de la Hoz B, Nunez-Lopez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy. 2007;37:1547–55. de Olano GD, de la Hoz B, Nunez-Lopez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy. 2007;37:1547–55.
52.
go back to reference Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226–32.PubMed Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226–32.PubMed
53.
go back to reference Matito A, Carter M. Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis? Curr Allergy Asthma Rep. 2015;15:22.PubMed Matito A, Carter M. Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis? Curr Allergy Asthma Rep. 2015;15:22.PubMed
54.
go back to reference Theoharides TC. Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol. 2009;22:642–51. Theoharides TC. Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol. 2009;22:642–51.
55.
go back to reference Seamens A, Taussig B, Penziner K, et al. Exploring the prevalence of learning disabilities in children with cutaneous mastocytosis: a pilot cohort study. J Am Acad Dermatol. 2016;75:1254–5.PubMed Seamens A, Taussig B, Penziner K, et al. Exploring the prevalence of learning disabilities in children with cutaneous mastocytosis: a pilot cohort study. J Am Acad Dermatol. 2016;75:1254–5.PubMed
56.
go back to reference Hemati P, Revah-Politi A, Bassan H, et al. Refining the phenotype associated with GNB1 mutations: clinical data on 18 newly identified patients and review of the literature. Am J Med Genet A. 2018;176:2259–75.PubMed Hemati P, Revah-Politi A, Bassan H, et al. Refining the phenotype associated with GNB1 mutations: clinical data on 18 newly identified patients and review of the literature. Am J Med Genet A. 2018;176:2259–75.PubMed
57.
go back to reference Alvarez-Twose I, Jara-Acevedo M, Morgado JM, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137:168-178e1.PubMed Alvarez-Twose I, Jara-Acevedo M, Morgado JM, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137:168-178e1.PubMed
58.
go back to reference Chan EC, Bai U, Kirshenbaum AS, et al. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. J Allergy Clin Immunol. 2014;134:178–87.PubMedPubMedCentral Chan EC, Bai U, Kirshenbaum AS, et al. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. J Allergy Clin Immunol. 2014;134:178–87.PubMedPubMedCentral
59.
go back to reference Greenberger S, Landov H, Confino Y, et al. Immunophenotype of pediatric-onset mastocytosis does not correlate with clinical course. Pediatr Dermatol. 2019;36:477–81.PubMed Greenberger S, Landov H, Confino Y, et al. Immunophenotype of pediatric-onset mastocytosis does not correlate with clinical course. Pediatr Dermatol. 2019;36:477–81.PubMed
60.
go back to reference de Paiva Silva RG, Tournier E, Sarian LO, et al. Prevalence of CD30 immunostaining in neoplastic mast cells: a retrospective immunohistochemical study. Medicine (Baltimore). 2018;97:e10642. de Paiva Silva RG, Tournier E, Sarian LO, et al. Prevalence of CD30 immunostaining in neoplastic mast cells: a retrospective immunohistochemical study. Medicine (Baltimore). 2018;97:e10642.
61.
go back to reference Van Anrooij B, Kluin PM, Oude Elberink JNG, et al. CD30 in systemic mastocytosis. Immunol Allergy Clin N Am. 2014;34:341–55. Van Anrooij B, Kluin PM, Oude Elberink JNG, et al. CD30 in systemic mastocytosis. Immunol Allergy Clin N Am. 2014;34:341–55.
62.
go back to reference Hollmann TJ, Brenn T, Hornick JL. CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis. Am J Surg Pathol. 2008;32:139–45.PubMed Hollmann TJ, Brenn T, Hornick JL. CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis. Am J Surg Pathol. 2008;32:139–45.PubMed
63.
go back to reference Lange M, Zawrocki A, Nedoszytko B, et al. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin? Int Arch Allergy Immunol. 2014;165:104–10.PubMed Lange M, Zawrocki A, Nedoszytko B, et al. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin? Int Arch Allergy Immunol. 2014;165:104–10.PubMed
64.
go back to reference Poirier E, Fraitag S, du Montcel TS, et al. CD30 expression in cutaneous lesions of systemic mastocytosis: clinical, biological, and histopathological analysis of 27 patients. JEADV. 2019;33:e310–47. Poirier E, Fraitag S, du Montcel TS, et al. CD30 expression in cutaneous lesions of systemic mastocytosis: clinical, biological, and histopathological analysis of 27 patients. JEADV. 2019;33:e310–47.
65.
go back to reference Carter M, Clayton S, Komarow H, et al. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol. 2015;136:1673–9.PubMedPubMedCentral Carter M, Clayton S, Komarow H, et al. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol. 2015;136:1673–9.PubMedPubMedCentral
66.
go back to reference Lange M, Zawadzka A, Schrörs S, et al. The role of serum tryptase in the diagnosis and monitoring of pediatric mastocytosis: a single center experience. Postepy Dermatol Alergol. 2017;34:306–12.PubMedPubMedCentral Lange M, Zawadzka A, Schrörs S, et al. The role of serum tryptase in the diagnosis and monitoring of pediatric mastocytosis: a single center experience. Postepy Dermatol Alergol. 2017;34:306–12.PubMedPubMedCentral
67.
go back to reference Seth N, Chinen J, Buheis G, et al. Serum tryptase levels in pediatric mastocytosis and association with systemic symptoms. Ann Allergy Asthma Immunol. 2020;125:219–21.PubMed Seth N, Chinen J, Buheis G, et al. Serum tryptase levels in pediatric mastocytosis and association with systemic symptoms. Ann Allergy Asthma Immunol. 2020;125:219–21.PubMed
68.
go back to reference Carter M, Bai Y, Ruiz Esteves K, et al. Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease. Br J Haematol. 2018;183:775–82.PubMed Carter M, Bai Y, Ruiz Esteves K, et al. Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease. Br J Haematol. 2018;183:775–82.PubMed
69.
go back to reference Czarny J, Zuk M, Zawrocki Z, et al. New approach to paediatric mastocytosis: implications of KIT D816V mutation detection in peripheral blood. Acta Derm Venereol. 2020;100:adv00149.PubMed Czarny J, Zuk M, Zawrocki Z, et al. New approach to paediatric mastocytosis: implications of KIT D816V mutation detection in peripheral blood. Acta Derm Venereol. 2020;100:adv00149.PubMed
70.
go back to reference Hussain SH. Pediatric mastocytosis. Curr Opin Pediatr. 2020;32:531–8.PubMed Hussain SH. Pediatric mastocytosis. Curr Opin Pediatr. 2020;32:531–8.PubMed
71.
go back to reference Renke J, Lange M, Dawicka J, et al. Hypogammaglobulinemias in infants and toddlers with mastocytosis – a new aspect to analyze? Pediatr Allergy Immunol. 2016;27:331–2.PubMed Renke J, Lange M, Dawicka J, et al. Hypogammaglobulinemias in infants and toddlers with mastocytosis – a new aspect to analyze? Pediatr Allergy Immunol. 2016;27:331–2.PubMed
72.
go back to reference Ertugrul B, Ozturk K, Gurkan O, Ertugrul A. Pediatric cutaneous mastocytosis and c-KIT mutation screening. Allergy Asthma Proc. 2019;40:123–8.PubMed Ertugrul B, Ozturk K, Gurkan O, Ertugrul A. Pediatric cutaneous mastocytosis and c-KIT mutation screening. Allergy Asthma Proc. 2019;40:123–8.PubMed
73.
go back to reference Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53.PubMed Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53.PubMed
74.
go back to reference Azaña JM, Torrelo A, Matito A. Update on mastocytosis (part 2): categories, prognosis, and treatment. Actas Dermosifiliogr. 2016;107:15–22.PubMed Azaña JM, Torrelo A, Matito A. Update on mastocytosis (part 2): categories, prognosis, and treatment. Actas Dermosifiliogr. 2016;107:15–22.PubMed
75.
go back to reference Siebenhaar F, Akin C, Bindslev-Jensen C, et al. Treatment strategies in mastocytosis. Immunol Allergy Clin N Am. 2014;34:433–47. Siebenhaar F, Akin C, Bindslev-Jensen C, et al. Treatment strategies in mastocytosis. Immunol Allergy Clin N Am. 2014;34:433–47.
76.
go back to reference Carter MC, Metcalfe DD, Matito A, et al. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a group report of the Mast Cells Disorder Committee, American Academy of Allergy and Immunology. J Allergy Clin Immunol. 2019;143:880–93.PubMed Carter MC, Metcalfe DD, Matito A, et al. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a group report of the Mast Cells Disorder Committee, American Academy of Allergy and Immunology. J Allergy Clin Immunol. 2019;143:880–93.PubMed
77.
go back to reference Ahmad N, Evans P, Lloyd-Thomas AR. Anesthesia in children with mastocytosis—a case based review. Paediatr Anaesth. 2009;19:97–107.PubMed Ahmad N, Evans P, Lloyd-Thomas AR. Anesthesia in children with mastocytosis—a case based review. Paediatr Anaesth. 2009;19:97–107.PubMed
78.
go back to reference Sánchez-Matas I, Matito A, de Olano GD, et al. Prevalence of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in 212 patients with mastocytosis in Spain. Allergy. 2009;64:551. Sánchez-Matas I, Matito A, de Olano GD, et al. Prevalence of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in 212 patients with mastocytosis in Spain. Allergy. 2009;64:551.
79.
go back to reference Carter MC, Uzzaman A, Scott LM. Pediatric mastocytosis: routine anesthetic management of a complex disease. Anesth Analg. 2008;107:422–7.PubMedPubMedCentral Carter MC, Uzzaman A, Scott LM. Pediatric mastocytosis: routine anesthetic management of a complex disease. Anesth Analg. 2008;107:422–7.PubMedPubMedCentral
80.
go back to reference Klein NJ, Misseldine S. Anesthetic considerations in pediatric mastocytosis: a review. J Anesth. 2013;27:588–98.PubMed Klein NJ, Misseldine S. Anesthetic considerations in pediatric mastocytosis: a review. J Anesth. 2013;27:588–98.PubMed
81.
go back to reference Hermans MAW, et al. Management around invasive procedures in mastocytosis: an update. Ann Allergy Asthma Immunol. 2017;119:304–9.PubMed Hermans MAW, et al. Management around invasive procedures in mastocytosis: an update. Ann Allergy Asthma Immunol. 2017;119:304–9.PubMed
82.
go back to reference James PD, Krafchik BR, Johnston AE. Cutaneous mastocytosis in children: anaesthetic considerations. Can J Anaesth. 1987;34:522–4.PubMed James PD, Krafchik BR, Johnston AE. Cutaneous mastocytosis in children: anaesthetic considerations. Can J Anaesth. 1987;34:522–4.PubMed
83.
go back to reference Matito A, Morgado JM, Sanchez-Lopez P, et al. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol. 2015;167:47–56.PubMed Matito A, Morgado JM, Sanchez-Lopez P, et al. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol. 2015;167:47–56.PubMed
84.
go back to reference Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. Anesthesiology. 2014;120:753–9.PubMed Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. Anesthesiology. 2014;120:753–9.PubMed
85.
go back to reference Parente R, Pucino V, Magliacane D, et al. Evaluation of vaccination safety in children with mastocytosis. Pediatr Allergy Immunol. 2017;28:93–5.PubMed Parente R, Pucino V, Magliacane D, et al. Evaluation of vaccination safety in children with mastocytosis. Pediatr Allergy Immunol. 2017;28:93–5.PubMed
86.
go back to reference Vlieg-Boerstra BJ, van der Heide S, Oude Elberink JNG, et al. Mastocytosis and adverse reactions to biogenic amines and histamine-releasing foods: what is the evidence? Neth J Med. 2005;63:244–9.PubMed Vlieg-Boerstra BJ, van der Heide S, Oude Elberink JNG, et al. Mastocytosis and adverse reactions to biogenic amines and histamine-releasing foods: what is the evidence? Neth J Med. 2005;63:244–9.PubMed
87.
go back to reference Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85:1185–96.PubMed Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85:1185–96.PubMed
88.
go back to reference Russell N, Jennings S, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: part 2—patient clinical experiences and beyond. J Allergy Clin Immunol Pract. 2019;7:1157–65.PubMed Russell N, Jennings S, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: part 2—patient clinical experiences and beyond. J Allergy Clin Immunol Pract. 2019;7:1157–65.PubMed
89.
go back to reference Jarkvist J, Brockow K, Gülen T. Low frequency of IgE-mediated food hypersensitivity in mastocytosis. J Allergy Clin Immunol Pract. 2020;8:3093–101.PubMed Jarkvist J, Brockow K, Gülen T. Low frequency of IgE-mediated food hypersensitivity in mastocytosis. J Allergy Clin Immunol Pract. 2020;8:3093–101.PubMed
90.
go back to reference Alvarez-Twose I, de Olano GD, Sanchez-Munoz L, et al. Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms. J Allergy Clin Immunol. 2010;125:1269–78.PubMed Alvarez-Twose I, de Olano GD, Sanchez-Munoz L, et al. Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms. J Allergy Clin Immunol. 2010;125:1269–78.PubMed
91.
go back to reference Bonadonna P, Scaffidi L. Hymenoptera anaphylaxis as a clonal mast cell disorder. Immunol Allergy Clin N Am. 2018;38:455–68. Bonadonna P, Scaffidi L. Hymenoptera anaphylaxis as a clonal mast cell disorder. Immunol Allergy Clin N Am. 2018;38:455–68.
92.
go back to reference Dölle-Bierke S, Siebenhaar F, Burmeister T, Worm M. Detection of KIT D816V mutation in patients with severe anaphylaxis and normal basal tryptase-first data from the Anaphylaxis Registry (NORA). J Allergy Clin Immunol. 2019;144(1448–50):e1. Dölle-Bierke S, Siebenhaar F, Burmeister T, Worm M. Detection of KIT D816V mutation in patients with severe anaphylaxis and normal basal tryptase-first data from the Anaphylaxis Registry (NORA). J Allergy Clin Immunol. 2019;144(1448–50):e1.
93.
go back to reference Yavuz ST, Sackensen C, Sahiner UM, et al. Importance of serum basal tryptase levels in children with insect venom allergy. Allergy. 2013;68:386–91.PubMed Yavuz ST, Sackensen C, Sahiner UM, et al. Importance of serum basal tryptase levels in children with insect venom allergy. Allergy. 2013;68:386–91.PubMed
94.
go back to reference Smith J, Murphy M, Funk T, et al. Epinephrine auto-injector for urticaria pigmentosa: a retrospective cohort study. In: Presented at Society of Pediatric Dermatology Annual Meeting, July 2019. Smith J, Murphy M, Funk T, et al. Epinephrine auto-injector for urticaria pigmentosa: a retrospective cohort study. In: Presented at Society of Pediatric Dermatology Annual Meeting, July 2019.
95.
go back to reference Greenhawt M, Gupta RS, Meadows JA, et al. Guiding principles for the recognition, diagnosis, and management of infants with anaphylaxis: an expert panel consensus. J Allergy Clin Immunol Pract. 2019;7:1148–56.PubMed Greenhawt M, Gupta RS, Meadows JA, et al. Guiding principles for the recognition, diagnosis, and management of infants with anaphylaxis: an expert panel consensus. J Allergy Clin Immunol Pract. 2019;7:1148–56.PubMed
96.
go back to reference Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393–414.PubMed Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393–414.PubMed
98.
go back to reference Turner PJ, Kemp AS, Rogers M, Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol. 2012;29:222–3.PubMed Turner PJ, Kemp AS, Rogers M, Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol. 2012;29:222–3.PubMed
99.
go back to reference Edwards AM, Capková S. Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant. BMJ Case Rep. 2011;29:bcr0220113910. Edwards AM, Capková S. Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant. BMJ Case Rep. 2011;29:bcr0220113910.
100.
go back to reference Vieira Dos Santos R, Magerl M, Martus P, et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol. 2010;162:674–6.PubMed Vieira Dos Santos R, Magerl M, Martus P, et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol. 2010;162:674–6.PubMed
101.
go back to reference Sokol KC, Ghazi A, Kelly BC, et al. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract. 2014;2:266–70.PubMed Sokol KC, Ghazi A, Kelly BC, et al. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract. 2014;2:266–70.PubMed
102.
go back to reference Jendoubi F, Gaudenzio N, Gallini A, et al. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy. 2020;50:654–61.PubMed Jendoubi F, Gaudenzio N, Gallini A, et al. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy. 2020;50:654–61.PubMed
103.
go back to reference Hughes J, Olynyc T, Chapdelaine H, et al. Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair(R)). Clin Exp Dermatol. 2018;43:573–6.PubMed Hughes J, Olynyc T, Chapdelaine H, et al. Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair(R)). Clin Exp Dermatol. 2018;43:573–6.PubMed
104.
go back to reference Distler M, Maul JT, Steiner UC, et al. Efficacy of omalizumab in mastocytosis: allusive indication obtained from a prospective, double-bline, multicenter study (XOLIMA study). Dermatology. 2020;20:1–11. Distler M, Maul JT, Steiner UC, et al. Efficacy of omalizumab in mastocytosis: allusive indication obtained from a prospective, double-bline, multicenter study (XOLIMA study). Dermatology. 2020;20:1–11.
105.
go back to reference Yankova R, Abadjieva T, Belovezhdov V. Cutaneous mastocytosis with persistent blistering: successful treatment with methylprednisolone and 3-year follow-up management. Dermatol Ther (Heidelb). 2015;5:145–50.PubMedPubMedCentral Yankova R, Abadjieva T, Belovezhdov V. Cutaneous mastocytosis with persistent blistering: successful treatment with methylprednisolone and 3-year follow-up management. Dermatol Ther (Heidelb). 2015;5:145–50.PubMedPubMedCentral
106.
go back to reference Ma Z, Tovar JP, Kwong KYC, Paek D. Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. Int Arch Allergy Immunol. 2010;153:413–8.PubMed Ma Z, Tovar JP, Kwong KYC, Paek D. Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. Int Arch Allergy Immunol. 2010;153:413–8.PubMed
107.
go back to reference Mashiah J, Harel A, Bodemer C, et al. Topical pimecrolimus for paediatric cutaneous mastocytosis. Clin Exp Dermatol. 2018;43:559–65.PubMed Mashiah J, Harel A, Bodemer C, et al. Topical pimecrolimus for paediatric cutaneous mastocytosis. Clin Exp Dermatol. 2018;43:559–65.PubMed
108.
go back to reference Patrizi A, Tabanelli M, Neri I, Virdi A. Topical corticosteroids versus “wait and see” in the management of solitary mastocytoma in pediatric patients: a long-term follow-up. Dermatol Ther. 2015;28:57–61.PubMed Patrizi A, Tabanelli M, Neri I, Virdi A. Topical corticosteroids versus “wait and see” in the management of solitary mastocytoma in pediatric patients: a long-term follow-up. Dermatol Ther. 2015;28:57–61.PubMed
109.
go back to reference Mateo JR. Mastocytoma: topical corticosteroid treatment. J Eur Acad Dermatol Venereol. 2001;15:492–4.PubMed Mateo JR. Mastocytoma: topical corticosteroid treatment. J Eur Acad Dermatol Venereol. 2001;15:492–4.PubMed
110.
go back to reference Barton J, Lavker RM, Schechter NM, Lazarus GS. Treatment of urticaria pigmentosa with corticosteroids. Arch Dermatol. 1985;121:1516–23.PubMed Barton J, Lavker RM, Schechter NM, Lazarus GS. Treatment of urticaria pigmentosa with corticosteroids. Arch Dermatol. 1985;121:1516–23.PubMed
111.
go back to reference Yung A. Flushing due to solitary cutaneous mastocytoma can be prevented by hydrocolloid dressings. Pediatr Dermatol. 2004;21:262–4.PubMed Yung A. Flushing due to solitary cutaneous mastocytoma can be prevented by hydrocolloid dressings. Pediatr Dermatol. 2004;21:262–4.PubMed
112.
go back to reference Brazzelli V, Grassi S, Merante S, et al. Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. Photodermatol Photoimmunol Photomed. 2016;32:238–46.PubMed Brazzelli V, Grassi S, Merante S, et al. Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. Photodermatol Photoimmunol Photomed. 2016;32:238–46.PubMed
113.
go back to reference Kinsler VA, Hawk JL, Atherton DJ. Diffuse cutaneous mastocytosis treated with psoralen photochemotherapy: case report and review of the literature. Br J Dermatol. 2005;152:179–80.PubMed Kinsler VA, Hawk JL, Atherton DJ. Diffuse cutaneous mastocytosis treated with psoralen photochemotherapy: case report and review of the literature. Br J Dermatol. 2005;152:179–80.PubMed
114.
go back to reference Piris-Villaespesa M, Alvarez-Twose I. Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. Front Pharmacol. 2020;11:443.PubMedPubMedCentral Piris-Villaespesa M, Alvarez-Twose I. Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. Front Pharmacol. 2020;11:443.PubMedPubMedCentral
115.
go back to reference Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2530–41.PubMed Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2530–41.PubMed
116.
go back to reference Liu M, Kohn L, Roach G, et al. Treatment of systemic mastocytosis in an infant with midostaurin. J Allergy Clin Immunol Pract. 2019;7(2929–31):e1. Liu M, Kohn L, Roach G, et al. Treatment of systemic mastocytosis in an infant with midostaurin. J Allergy Clin Immunol Pract. 2019;7(2929–31):e1.
117.
go back to reference Morren MA, Hoppé A, Renard M, et al. Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. J Pediatr. 2013;162:205–7.PubMed Morren MA, Hoppé A, Renard M, et al. Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. J Pediatr. 2013;162:205–7.PubMed
118.
go back to reference Hoffmann KM, Moser A, Lohse P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood. 2008;112:1655–7.PubMed Hoffmann KM, Moser A, Lohse P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood. 2008;112:1655–7.PubMed
Metadata
Title
Pediatric Mastocytosis: Recognition and Management
Author
Julie V. Schaffer
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 2/2021
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-020-00581-5

Other articles of this Issue 2/2021

American Journal of Clinical Dermatology 2/2021 Go to the issue